Medication Use & Patient Safety
“Our work gives patients and providers evidence about the outcomes of medication use — both harmful and beneficial — to help them make informed personal decisions about prescription drug use.”
Sascha Dublin, MD, PhD
Kaiser Permanente Washington Health Research Institute Senior Investigator
Physician, Washington Permanente Medical Group, Internal Medicine
Research overview
Americans are using more prescription drugs than ever. Consequently, they’re coping with more side effects, drug interactions, and costs, especially if they’re using multiple medications. Kaiser Permanente Washington Health Research Institute (KPWHRI) scientists are on the forefront of answering questions about these concerns. We’re studying the beneficial and harmful effects of medications in real-world settings, and innovating better ways to manage and monitor drug use.
The institute contributes to national initiatives to monitor medication safety as well as providing information to help doctors and patients weigh the risks and benefits of various prescription drugs.
Funders of KPWHRI medication use and patient safety research include the Centers for Disease Control and Prevention, the U.S. Food and Drug Administration, the National Institutes of Health, the Patient-Centered Outcomes Research Institute, and other sources. A few projects include:
- Studying whether commonly used medications, including oral contraceptives, are associated with the risk of developing COVID-19 infection or severe disease
- Exploring patient and clinical risk factors for opioid misuse, abuse, and addiction
- Evaluating an intervention for patients taking long-term high-dose opioids to successfully taper their use without negatively impacting pain management and quality of life
- Proactive monitoring of medical products through the FDA Sentinel Initiative
- Studying medication safety for pregnant people and older adults
- Monitoring vaccine safety and effectiveness
- Investigating how medications affect risk of cognitive decline and dementia in late life
- Reaching out to inform patients and providers about the risks of, and alternatives to, commonly used medications that may contribute to falls, including over-the-counter antihistamines
Recent publications on Medication Use & Patient Safety
Nelson JC, Cook AJ, Yu O, Dominguez C, Zhao S, Greene SK, Fireman BH, Jacobsen SJ, Weintraub ES, Jackson LA. Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data. Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:62-71. doi: 10.1002/pds.2324. PubMed
Curtis LH, Weiner MG, Boudreau DM, Cooper WO, Daniel GW, Nair VP, Raebel MA, Beaulieu NU, Rosofsky R, Woodworth TS, Brown JS. Design considerations, architecture, and use of the Mini-Sentinel distributed data system. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 1:23-31. doi: 10.1002/pds.2336. PubMed
Fireman B, Toh S, Butler MG, Go AS, Joffe HV, Graham DJ, Nelson JC, Daniel GW, Selby JV. A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 1:282-90. doi: 10.1002/pds.2337. PubMed
Cook AJ, Tiwari RC, Wellman RD, Heckbert SR, Li L, Heagerty P, Marsh T, Nelson JC. Statistical approaches to group sequential monitoring of postmarket safety surveillance data: current state of the art for use in the Mini-Sentinel pilot. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 1:72-81. doi: 10.1002/pds.2320. PubMed
Platt R, Carnahan RM, Brown JS, Chrischilles E, Curtis LH, Hennessy S, Nelson JC, Racoosin JA, Robb M, Schneeweiss S, Toh S, Weiner MG. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 1:1-8. doi: 10.1002/pds.2343. PubMed
Researchers in Medication Use & Patient Safety
 Sascha Dublin, MD, PhDSenior Investigator |
 Jessica Chubak, PhDSenior Investigator |
 Andrea J. Cook, PhDSenior Biostatistics Investigator |
 Rita Mangione-Smith, MD, MPHExecutive Director and Senior Investigator, KPWHRI; Vice President for Research and Health Care Innovation, Kaiser Permanente Washington |
 Jennifer C. Nelson, PhDDirector, Biostatistics; Senior Investigator |
 David E. Arterburn, MD, MPHSenior Investigator |
 Susan M. Shortreed, PhDSenior Biostatistics Investigator |
 Lisa A. Jackson, MD, MPHSenior Investigator |
 Karen Wernli, PhDSenior Investigator |
 Onchee Yu, MSPrincipal Collaborative Biostatistician |
 Rod L. Walker, MSPrincipal Collaborative Biostatistician |
 Robert D. Wellman, MSPrincipal Collaborative Biostatistician |
 Gaia Pocobelli, PhDSenior Collaborative Scientist |
 Laura Harrington, PhD, MPHAssistant Investigator |
 Jennifer F. Bobb, PhDAssociate Biostatistics Investigator |
 Weiwei Zhu, MSSenior Collaborative Biostatistician |
 Paige D. Wartko, PhD, MPHSenior Collaborative Scientist |
 Maricela Cruz, PhDAssistant Biostatistics Investigator |
 Brian D. Williamson, PhDAssistant Biostatistics Investigator |
 Noorie Hyun, PhDAssociate Biostatistics Investigator |
 Laurel Hansell, MA, MPHCollaborative Scientist |
 Jess Mogk, MPHCollaborative Scientist |
 Annie Piccorelli, PhDSenior Collaborative Biostatistician |
Affiliate researchers
Susan Heckbert, MD, PhD
University of Washington (UW) Department of Epidemiology; UW Cardiovascular Health Research Unit
David Siscovick, MD, MPH
UW Department of Medicine; UW Department of Epidemiology; UW Cardiovascular Health Research Unit
Leslie Spangler, PhD
Amgen
Research roundup
What's new in cannabis use research?
Use in pregnancy and screening in primary care studied by KPWHRI’s Kiel, Matson, and Lapham.
Research
IUD perforation: Rare but important to know about
New study results in more precise language in the federally mandated warning about this possibility.
Research
New findings on treating hypertension in pregnancy
A study led by Dr. Sascha Dublin finds similar outcomes for 3 hypertension medications, filling an evidence gap.
COVID-19 treatments
New report supports value of COVID-19 drugs
A team led by KPWHRI's Kai Yeung, PharmD, PhD, reviewed trial results for cost-effectiveness of 3 treatments.
Prescription overload
Deprescribing: Less may be more
Dr. Sascha Dublin explains why sometimes not taking medications may be a safer and healthier choice.
Electronic health records
EHR study offers insights on medical cannabis use
New research examines providers’ notes to understand patients’ cannabis use and health conditions.
Research
HEAL responds to double crisis: Opioids and COVID-19
Health care is increasingly online—KPWHRI is studying telehealth options for opioid use disorder and chronic pain.
research
Medication in pregnancy: Better data for healthier kids
Researchers need much bigger data sets to find outcomes that matter, Dr. Sascha Dublin and colleagues write in Pediatrics.
profile
What inspires Sascha Dublin’s maternal health research?
Evidence from Dr. Dublin’s work helps patients and doctors make the best care choices in pregnancy.
drug safety
FDA to expand drug-safety monitoring capacity
New funding will establish an innovation center, to be led by Harvard Pilgrim in partnership with KPWHRI and others.
medication safety
Using phentermine for weight loss longer term found to be safe, effective
Dr. David Arterburn discusses reassuring news from his PCORnet study of the most widely used anti-obesity drug in the United States.
aging & geriatrics
Do drugs cause falls for adults with dementia?
Researchers find a relationship between prescribed central nervous system-active medications and increased risk of falling among older people with dementia.
Land Acknowledgment
Our Seattle offices sit on the occupied land of the Duwamish and by the shared waters of the Coast Salish people, who have been here thousands of years and remain. Learn about practicing land acknowledgment.